About MyoKardia
MyoKardia is a Healthcare company based in San Francisco (United States) founded in 2012, and was acquired by Bristol-Myers Squibb in October 2020. Specialized drugs are developed for genetic heart diseases. MyoKardia has raised $98 million across 5 funding rounds from investors including JPMorgan Chase, Sanofi and Bristol-Myers Squibb. The company has 224 employees. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Drugs and Diversified. Its legal entity is MYOKARDIA INC. Its competitors include Tenaya Therapeutics, Cellino and Eiger BioPharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
MyoKardia was founded in 2012 in San Francisco, United States, within the biotechnology sector. Operations center on creating therapies for cardiovascular conditions, including hypertrophic and dilated cardiomyopathy. A candidate treatment, MYK-224, targets cardiac myosin to limit excessive cross-bridge formation in hypertrophic cardiomyopathy. This mechanism seeks to control contractility, support relaxation, and lower variability in drug kinetics compared to prior options.
- Headquarters San Francisco, United States
- Employees 224
- Stage Acquired
- SectorsHealthcare
- Website myokardia.com
- Social LinkedIn
- Acquired by Bristol-Myers Squibb (Oct 2020)
- Legal Name Myokardia Inc
- Annual Revenue$33.56 M (USD)193as on Dec 31, 2018
- Net Profit-$276.21 M (USD)-308as on Dec 31, 2019
- EBITDA-$287.83 M (USD)-291as on Dec 31, 2019
- Total Equity Funding$98M (USD)
in 5 rounds
- InvestorsJPMorgan Chase
& 5 more
- Employee Count224
- Acquired byBristol-Myers Squibb
(Oct 2020)
Funding Insights of MyoKardia
MyoKardia has successfully raised a total of $98M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $98M
- Total Rounds 5
- First Round $38M
(Sep 2012)
- Investors Count 5
All 5 funding rounds of MyoKardia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2016 | Post-IPO | – | – | ||
| Apr 2015 | $46M | Series B | – | Casdin Capital, Sanofi | – |
| Aug 2014 | $10M | Series B | – | – | – |
| Sep 2012 | $4M | Series A | – | – | – |
| Sep 2012 | $38M | Series A | – | – |
6 investors in total: 6 institutional.
Investors in MyoKardia
MyoKardia has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include JPMorgan Chase, Sanofi and Bristol-Myers Squibb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Financial services are provided to consumers and corporations worldwide. | 2000 | jpmorganchase.com | New York, United States | |
Pharmaceutical and nutraceutical products are developed across seven therapeutic areas. | 1973 | sanofi.com | Paris, France | |
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | 1887 | bms.com | New York, United States |
Investor details for MyoKardia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MyoKardia
1417 people are tracked at MyoKardia (870 in leadership, 11 in board & advisors, 536 in team); the tracked headcount is 224.
| Name | Role | Group |
|---|---|---|
Lakshmikant Bajpai | Director And Head Of Analytical Research & Development | Leadership |
Tughan Demirbilek | Head Of Strategy & Operations Intercontinental Region | Leadership |
Elaina Gillule | Human Resources Business Partner- R&d - Global Development Operations | Leadership |
Mark L Clarke | Associate Director Cell Therapy Development | Leadership |
Frank Marra | Vice President, Worldwide Commercialization Operations | Leadership |
Alex Turoczi | Director, End To End AI Marketing Integration Lead, Worldwide Commercialization Excellence | Leadership |
Yolanda Caringal | Senior Director | Leadership |
Nitin Bindal | Business Unit Director - Oncology And Hematology | Leadership |
Stephane Strebelle | Executive Director Finance, US Commercialization Fp&a | Leadership |
Tyler Longmire | Director | Leadership |
Lisa Evans | Director, Omnichannel Strategy, Neuroscience | Leadership |
Federico L. | Senior Director, Value Chain Analytics | Leadership |
Kevan J. Evans II | Director | Global Business Performance, Strategy & Excellence; People Organization | Leadership |
Shayla O. | Associate Director, People Services Communications | People & Culture Internal Comms | Leadership |
Kami Wagner | Director, R&d Quality- Clinical Auditing | Leadership |
Kald A. | Head Of Worldwide Medical - Oncology | Leadership |
Joanna Wolkowski | Head Of Global Pricing, Health Systems Analytics, And Reimbursement Operations | Leadership |
Imara Charles | Vice President, Chief Of Staff, Global Product Development And Supply | Leadership |
Christian Lamont | Executive Director, Automated Product Market Compliance | Leadership |
Shuka F. | Associate Director, Global Quality - IT Quality Assurance | Leadership |
1397 more people are available in the full profile.
Complete people profiles for MyoKardia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of MyoKardia
5 dated milestones of MyoKardia across 8 years, from founding to its latest funding, stage changes and deals.
- Founded MyoKardia is founded.
- Funding First funding round of $38.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO,.
- Exit Acquired by Bristol-Myers Squibb.
Competitors of MyoKardia
MyoKardia has 3 listed competitors in our database, 3 of them funded. They include Tenaya Therapeutics, Cellino and Eiger BioPharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| eigerbio.com | 2000 | San Carlos, United States | $8.9M | 56 | Developer of antiviral agents against targets in the treatment of hepatitis |
Detailed competitors of MyoKardia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of MyoKardia
Websites that share an audience with MyoKardia (myokardia.com).
Websites whose visitors overlap most with MyoKardia. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
circres.ahajournals.org | circres.ahajournals.org | 100% | – | ||
| hhmi.org | 84% | 426.7K | #102,183 | View details | |
| cvrx.com | 76% | 3.5K | #5,799,167 | View details |
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as MyoKardia (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Myokardia
Complete news archive for MyoKardia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MyoKardia
MyoKardia was founded in 2012.
MyoKardia is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
MyoKardia is a funded company, having raised a total of $98M across 5 funding rounds to date. The company's 1st funding round was a Series A of $38M, raised on Sep 2012.
MyoKardia has 224 employees.
Annual revenue of MyoKardia is $33.56M as on Dec 31, 2018.
MyoKardia was founded in 2012 in San Francisco, United States, within the biotechnology sector. Operations center on creating therapies for cardiovascular conditions, including hypertrophic and dilated cardiomyopathy. A candidate treatment, MYK-224, targets cardiac myosin to limit excessive cross-bridge formation in hypertrophic cardiomyopathy. This mechanism seeks to control contractility, support relaxation, and lower variability in drug kinetics compared to prior options.
MyoKardia's top competitors include Tenaya Therapeutics, Cellino and Eiger BioPharmaceuticals.
MyoKardia has 6 investors. Key investors include JPMorgan Chase, Sanofi, Bristol-Myers Squibb, Perceptive Advisors, and Casdin Capital.
MyoKardia operates through Myokardia Inc.
Yes. MyoKardia was acquired by Bristol-Myers Squibb in October 2020.